

Savings Program

for eligible commercially insured patients

Pay \$5 per prescription fill

Maximum program benefit per calendar year shall apply across all oral PAH therapies in the program. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year. Offer subject to change or end without notice. Restrictions, including monthly maximums, may apply. Offer not valid for TRACLEER® in CA or MA, or for MA residents (62.5 mg and 125 mg only). Participate without sharing your income information. See program requirements on next page.

Janssen CarePath
SAVINGS PROGRAM

Opsumit
macitentan tablets 10 mg

Opsynvi
macitentan/tadalafil
10 mg/40 mg tablets

Tracleer
BOSENTAN
62.5 mg/125 mg Tablets
32 mg Tablets for Oral Suspension

Uptravi
selexipag
tablets 200, 1600 mg

BIN: 610020 **GROUP:** 99992138
ID:

Please see the full Prescribing Information and Medication Guides for OPSUMIT® and OPSYNVI® including an Important Warning about Serious Birth Defects. Please read the full Prescribing Information, including Boxed Warning about liver injury and birth defects, and Medication Guide for TRACLEER®. Please read the full Prescribing Information and Patient Product Information for UPTRAVI®.

PROGRAM REQUIREMENTS APPLY.

Get savings on your out-of-pocket medication costs for OPSUMIT®, OPSYNVI®, TRACLEER®, or UPTRAVI®. Depending on the health insurance plan, savings may apply toward co-pay, co-insurance, or deductible.

Call a Janssen CarePath Care Coordinator at **866-228-3546** or visit JanssenCarePath.com for more information about affordability programs that may be available.

Please see the full Prescribing Information for [OPSUMIT®](#) and [OPSYNVI®](#) and Medication Guides for [OPSUMIT®](#) and [OPSYNVI®](#), including an Important Warning about Serious Birth Defects. Please read the full Prescribing Information, including Boxed Warning about liver injury and birth defects, for [TRACLEER®](#) and Medication Guide for [TRACLEER®](#). Please read full Prescribing Information for [UPTRAVI®](#) and Patient Product Information for [UPTRAVI®](#).

Savings Program

Am I eligible?

You may be eligible for the Janssen CarePath Oral PAH Savings Program if you:

- Are age 18 or older (age 3 or older for TRACLEER® [bosentan] 32 mg), use commercial or private health insurance for OPSUMIT® (macitentan), OPSYNVI® (macitentan and tadalafil), UPTRAVI® (selexipag), or TRACLEER®, and must pay an out-of-pocket cost for your medication
- (Female patients only) Are enrolled in the Macitentan-Containing Products REMS Program for OPSUMIT® or OPSYNVI®. Learn more at MacitentanREMS.com
- Are enrolled in the Bosentan REMS Program for TRACLEER®. Learn more at BosentanREMSProgram.com

Some health plans have programs or benefit designs known as “accumulators” or “maximizers.” These programs divert patient assistance funds away from patients.

- Accumulators don’t allow patient assistance to count toward the patient’s deductible and out-of-pocket maximum until the maximum value of the patient assistance is reached.
- Maximizers also don’t allow patient assistance to count toward the patient’s deductible and out-of-pocket maximum. Maximizers apply the full value of the patient assistance over the year. This could be either the same amount each month or a larger amount early in the year that tapers off, without allowing any of those funds to count toward the patient’s annual deductible or out-of-pocket maximum.
- The Janssen CarePath Savings Program is designed solely for the benefit of the patient. Thus, Janssen reserves the right to reduce the Janssen CarePath Savings Program maximum benefit for patients in an accumulator or maximizer program or benefit design, except where prohibited by law.

In addition, some health plans have “non-essential health benefit maximizers” that conflict with the program requirements of the Janssen CarePath Savings Program.

- These programs or benefit designs, like the services offered by SaveOnSP, classify certain specialty medicines such as OPSUMIT®, OPSYNVI®, UPTRAVI®, or TRACLEER® as “non-essential.” This takes away protections for patients provided by the Affordable Care Act (ACA) related to maximum out-of-pocket limits.
- The Janssen CarePath Savings Program is designed solely for the benefit of the patient. If your insurance company or health plan partners with SaveOnSP, then except where prohibited by law, you will not be eligible for, and you agree not to use, the Janssen CarePath Savings Program.
- Please let Janssen CarePath know if your insurance company or health plan has one of these programs or benefit designs, including SaveOnSP, by calling 866-228-3546 to discuss your options. Since you may not know you are subject to one of these programs or benefit designs when you enroll in Janssen CarePath, Janssen will monitor your utilization.
- Janssen reserves the right to discontinue cost support if you no longer meet eligibility requirements.
- If your health plan removes OPSUMIT®, OPSYNVI®, UPTRAVI®, or TRACLEER® from its partnership with SaveOnSP or other non-essential health benefit maximizer, you may be eligible to be reinstated in the Janssen CarePath Savings Program.

By utilizing this Savings Program, you accept and agree to abide by these program requirements. Any individual or entity who enrolls or assists in the enrollment of a patient in the Savings Program represents that the patient meets the eligibility criteria and other requirements described.

Please see the full Prescribing Information for [OPSUMIT®](#) and [OPSYNVI®](#) and Medication Guides for [OPSUMIT®](#) and [OPSYNVI®](#), including an Important Warning about Serious Birth Defects. Please read the full Prescribing Information, including Boxed Warning about liver injury and birth defects, for [TRACLEER®](#) and Medication Guide for [TRACLEER®](#). Please read full Prescribing Information for [UPTRAVI®](#) and Patient Product Information for [UPTRAVI®](#).

Savings Program (cont'd)

Other requirements

- This program is only for people age 18 or older (age 3 or older for TRACLEER® 32 mg) using commercial or private health insurance who must pay an out-of-pocket cost for their Janssen medication. This includes plans from the Health Insurance Marketplace. This program is not for people who use any state or federal government-funded healthcare program. Examples of these programs are Medicare, Medicaid, TRICARE, Department of Defense, and Veterans Administration.
- By enrolling in this program, you agree that this program is intended solely for the benefit of you, the patient. You may not seek payment for the value received from this program from any health plan, patient assistance foundation, flexible spending account, or healthcare savings account.
- You must meet the program requirements every time you use the Savings Program.
- Program terms will expire at the end of each calendar year. The program may change or end without notice, including in specific states. Offer not valid for TRACLEER® in CA or MA or for MA residents (for 62.5 mg and 125 mg only).
- Program participants are subject to an annual maximum benefit. Program benefits are set at the discretion of Janssen and may change without notice.
- Patients who are subject to programs, health plans, or benefits that claim to **reduce** their patients' out-of-pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer-sponsored co-pay assistance for such drugs will be subject to a reduced annual maximum program benefit per calendar year (not applicable to patients in Maine).
- Patients who are subject to programs, health plans, or benefits that claim to **eliminate** their out-of-pocket costs are not eligible for the Janssen CarePath Savings Program, because this program is only for people who must pay an out-of-pocket cost for OPSUMIT®, OPSYNVI®, UPTRAVI®, or TRACLEER®.
- Notwithstanding any other term of this program, patients who are members of health plans that partner with SaveOnSP, or who are subject to services administered by SaveOnSP, are not eligible for the Janssen CarePath Savings Program. If your health plan removes OPSUMIT®, OPSYNVI®, UPTRAVI®, or TRACLEER® from its partnership with SaveOnSP, you may be eligible for the Janssen CarePath Savings Program.
- To use this program, you must follow any health plan requirements, including telling your health plan how much co-payment support you get from this program, if required. By using the Savings Program, you confirm that you have read, understood, and agree to the program requirements on this page, and you are giving permission for information related to your Savings Program transactions to be shared with your healthcare provider(s). These transactions include rebates and any funds placed on the card or balance remaining on the card.
- Before you enroll in the program, you will be asked to provide personal information that may include your name, address, phone number, email address, and information related to your prescription medication insurance and treatment. This information is needed for Actelion Pharmaceuticals US, Inc., and our service providers to enroll you in the Janssen CarePath Savings Program. We may also use the information you give us to learn more about the people who use OPSUMIT®, OPSYNVI®, UPTRAVI®, or TRACLEER®, and to improve the information we give them. Actelion Pharmaceuticals US, Inc. will not share your information with anyone else except where legally allowed.
- This program offer may not be used with any other coupon, discount, prescription savings card, free trial, or other offer. Offer good only in the United States and the Commonwealth of Puerto Rico, excluding states noted above. Void where prohibited, taxed, or limited by law.

You may end your participation in Janssen CarePath at any time by calling 866-228-3546.



Need
help?

Call **866-228-3546**
Monday–Friday, 8:00 AM–8:00 PM ET
Multilingual phone support available

Please see the full Prescribing Information for [OPSUMIT®](#) and [OPSYNVI®](#) and Medication Guides for [OPSUMIT®](#) and [OPSYNVI®](#), including an Important Warning about Serious Birth Defects. Please read the full Prescribing Information, including Boxed Warning about liver injury and birth defects, for [TRACLEER®](#) and Medication Guide for [TRACLEER®](#). Please read full Prescribing Information for [UPTRAVI®](#) and Patient Product Information for [UPTRAVI®](#).